FDA Approved: EOVIST — Original Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved EOVIST (gadoxetate disodium) through an original NDA for use as an MRI contrast agent to enhance liver imaging and help detect focal liver lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Neoplasms
• Liver Disease

Drugs mentioned

• EOVIST (GADOXETATE DISODIUM)

Snippet

ORIG AP for EOVIST (GADOXETATE DISODIUM)